SMT201500201B - Nuovi mutanti di prongf e loro usi per la produzione di beta-ngf - Google Patents

Nuovi mutanti di prongf e loro usi per la produzione di beta-ngf

Info

Publication number
SMT201500201B
SMT201500201B SM201500201T SM201500201T SMT201500201B SM T201500201 B SMT201500201 B SM T201500201B SM 201500201 T SM201500201 T SM 201500201T SM 201500201 T SM201500201 T SM 201500201T SM T201500201 B SMT201500201 B SM T201500201B
Authority
SM
San Marino
Prior art keywords
beta
new
ngf production
prongf mutants
prongf
Prior art date
Application number
SM201500201T
Other languages
English (en)
Italian (it)
Inventor
Susan Lorey
Bernhard Janowski
Heiko Pultke
Daniela Kathmann
Antje Parthier
Andreas Anton
Original Assignee
Wacker Chemie Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47428641&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201500201(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wacker Chemie Ag filed Critical Wacker Chemie Ag
Publication of SMT201500201B publication Critical patent/SMT201500201B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • C07K14/48Nerve growth factor [NGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/185Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1136General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by reversible modification of the secondary, tertiary or quarternary structure, e.g. using denaturating or stabilising agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • C07K1/16Extraction; Separation; Purification by chromatography
    • C07K1/165Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SM201500201T 2011-12-19 2015-08-20 Nuovi mutanti di prongf e loro usi per la produzione di beta-ngf SMT201500201B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP11194208 2011-12-19
EP12805695.9A EP2672984B1 (en) 2011-12-19 2012-12-19 Novel prongf mutants and uses thereof in the production of beta-ngf
PCT/EP2012/076251 WO2013092776A1 (en) 2011-12-19 2012-12-19 Novel prongf mutants and uses thereof in the production of beta-ngf

Publications (1)

Publication Number Publication Date
SMT201500201B true SMT201500201B (it) 2015-10-30

Family

ID=47428641

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201500201T SMT201500201B (it) 2011-12-19 2015-08-20 Nuovi mutanti di prongf e loro usi per la produzione di beta-ngf

Country Status (28)

Country Link
US (3) US9617322B2 (no)
EP (2) EP2672984B1 (no)
JP (4) JP6039146B2 (no)
KR (2) KR20160120788A (no)
CN (2) CN104203264B (no)
AU (1) AU2012357052B2 (no)
BR (1) BR112014014913B1 (no)
CA (1) CA2859262C (no)
CY (2) CY1117016T1 (no)
DK (2) DK2907521T3 (no)
EA (1) EA031333B1 (no)
ES (2) ES2657344T3 (no)
HK (1) HK1202055A1 (no)
HR (2) HRP20150900T1 (no)
HU (2) HUE027245T2 (no)
IL (1) IL233137A0 (no)
LT (1) LT2907521T (no)
MX (2) MX370861B (no)
NO (1) NO2907521T3 (no)
PL (2) PL2672984T3 (no)
PT (2) PT2907521T (no)
RS (2) RS56893B1 (no)
SG (2) SG10201605028VA (no)
SI (2) SI2672984T1 (no)
SM (1) SMT201500201B (no)
TR (1) TR201802360T4 (no)
WO (1) WO2013092776A1 (no)
ZA (1) ZA201403753B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2657344T3 (es) 2011-12-19 2018-03-02 Wacker Chemie Ag Nuevos mutantes de proNGF y usos de los mismos en la producción de beta-NGF
WO2015038582A2 (en) * 2013-09-11 2015-03-19 New York University Methods and compositions for treating bone diseases
EP3406259A1 (en) 2017-05-24 2018-11-28 Dompé farmaceutici S.p.A. Neurotrophins for use in the treatment of hearing loss
CN108456681B (zh) * 2018-03-26 2019-10-11 江苏中新医药有限公司 高效表达重组人神经生长因子的基因组合
US20210079053A1 (en) 2018-04-27 2021-03-18 Chiesi Farmaceutici Spa Production of nerve growth factor (ngf) and of muteins thereof
CN112334151A (zh) * 2018-06-29 2021-02-05 学校法人同志社 包含恩利卡生的制剂
JP2022502359A (ja) 2018-09-17 2022-01-11 キエージ・フアルマチエウテイチ・エツセ・ピ・ア 皮膚科障害の処置のための薬剤
IT201900014646A1 (it) * 2019-08-12 2021-02-12 Consiglio Nazionale Ricerche Peptide neurotrofico resistente alle proteasi per il trattamento terapeutico di patologie neurodegenerative e/o cutanee
CA3147828A1 (en) * 2019-09-17 2021-03-25 Bruno Pietro Imbimbo Agent for use in treatment or prevention of ophthalmic disorders
IL302317A (en) 2020-10-28 2023-06-01 Dompe Farm Spa Pharmaceutical packaging including polypropylene containers and aqueous formulations of NGF packed in them
EP4039269A1 (en) 2021-02-05 2022-08-10 Dompe' Farmaceutici S.P.A. Ngf isoform for use in the treatment of ocular pathologies
IL307622A (en) 2021-04-13 2023-12-01 Domp? Farm S P A Treatment of neuropathic corneal pain with NGF
EP4311554A1 (en) 2022-07-29 2024-01-31 Dompé farmaceutici S.p.a. Combination for use in ophthalmology
EP4316505A1 (en) 2022-08-05 2024-02-07 Dompé farmaceutici S.p.a. Intranasal administration of ngf for the treatment of sensorineural hearing loss
EP4342485A1 (en) 2022-09-23 2024-03-27 Dompe' Farmaceutici S.P.A. Ngf for the treatment of spasticity

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4139000A1 (de) * 1991-11-27 1993-06-03 Boehringer Mannheim Gmbh Verfahren zur gentechnologischen herstellung von biologisch aktivem ss-ngf
ES2213861T3 (es) 1998-10-09 2004-09-01 Scil Proteins Gmbh Procedimiento de obtencion de ngf-beta activa.
US20030040082A1 (en) 2001-02-16 2003-02-27 Mark Tuszynski Mutant pro-neurotrophin with improved activity
US7507799B2 (en) 2001-05-25 2009-03-24 Cornell Research Foundation, Inc. High affinity ligand for p75 neurotrophin receptor
DE10360483B4 (de) 2003-12-22 2007-11-15 Scil Proteins Gmbh Expressionsvektor und dessen Verwendung
ES2315842T3 (es) 2004-01-19 2009-04-01 Nsgene A/S Celulas terapeuticas humanas que secretan factor de crecimiento nervioso.
US20080050776A1 (en) 2006-05-26 2008-02-28 Kenneth Neet Stable mutated pro nerve growth factors
CN101260398B (zh) * 2007-03-07 2013-06-05 舒泰神(北京)生物制药股份有限公司 神经生长因子基因定位改造动物及其制备方法和应用
ES2657344T3 (es) * 2011-12-19 2018-03-02 Wacker Chemie Ag Nuevos mutantes de proNGF y usos de los mismos en la producción de beta-NGF

Also Published As

Publication number Publication date
EP2672984B1 (en) 2015-05-27
SG11201402585PA (en) 2014-10-30
SG10201605028VA (en) 2016-07-28
MX2014007317A (es) 2014-11-25
CA2859262A1 (en) 2013-06-27
MX353074B (es) 2017-12-19
CY1119926T1 (el) 2018-12-12
NZ627054A (en) 2015-06-26
HUE027245T2 (en) 2016-10-28
US9617322B2 (en) 2017-04-11
ES2545701T3 (es) 2015-09-15
KR20140103318A (ko) 2014-08-26
WO2013092776A1 (en) 2013-06-27
US20150087020A1 (en) 2015-03-26
US10308694B2 (en) 2019-06-04
KR101837802B1 (ko) 2018-03-12
JP6622683B2 (ja) 2019-12-18
HRP20150900T1 (hr) 2015-10-09
IL233137A0 (en) 2014-07-31
CN104203264B (zh) 2018-08-28
BR112014014913A2 (pt) 2017-06-13
HK1202055A1 (en) 2015-09-18
EP2907521B1 (en) 2017-11-22
HRP20180307T1 (hr) 2018-03-23
AU2012357052B2 (en) 2015-06-25
CY1117016T1 (el) 2017-04-05
AU2012357052A1 (en) 2014-07-24
SI2907521T1 (en) 2018-03-30
EP2672984A1 (en) 2013-12-18
JP2017071611A (ja) 2017-04-13
PL2907521T3 (pl) 2018-04-30
RS54220B1 (en) 2015-12-31
US20200031893A1 (en) 2020-01-30
KR20160120788A (ko) 2016-10-18
JP2019006781A (ja) 2019-01-17
SI2672984T1 (sl) 2015-11-30
ES2657344T3 (es) 2018-03-02
NO2907521T3 (no) 2018-04-21
MX370861B (es) 2020-01-08
US20160244496A1 (en) 2016-08-25
PT2672984E (pt) 2015-10-01
BR112014014913B1 (pt) 2020-12-01
EA201491155A1 (ru) 2015-01-30
PT2907521T (pt) 2018-02-22
DK2907521T3 (en) 2018-03-05
TR201802360T4 (tr) 2018-03-21
EA031333B1 (ru) 2018-12-28
JP6039146B2 (ja) 2016-12-07
PL2672984T3 (pl) 2015-10-30
LT2907521T (lt) 2018-05-10
JP2015501828A (ja) 2015-01-19
CN104203264A (zh) 2014-12-10
ZA201403753B (en) 2015-11-25
DK2672984T3 (en) 2015-08-24
EP2907521A1 (en) 2015-08-19
CN109400693A (zh) 2019-03-01
JP2019011330A (ja) 2019-01-24
HUE036265T2 (hu) 2018-06-28
RS56893B1 (sr) 2018-04-30
CA2859262C (en) 2021-04-06

Similar Documents

Publication Publication Date Title
SMT201500201B (it) Nuovi mutanti di prongf e loro usi per la produzione di beta-ngf
SMT201600375B (it) Procedimento per la produzione di estetrolo
ZA201306005B (en) Novel sulfonaminoquinoline hepcidin antagonists
EP2726498A4 (en) PHOTOACTIVABLE RECEPTORS AND USES THEREOF
DK2785695T3 (da) Nye bicykliske dihydroisoquinolin-1-on-derivater
BR112013021332A2 (pt) conjunto de preparação e máquina de produção de bebidas compreendendo o dito conjunto
EP2683668A4 (en) HOLLOW MICROSPHERES
SMT201400052B (it) Bevande alle mandorle e metodi per la loro produzione
DK2632598T3 (da) Valsemølle
ES2972550T3 (es) Un proceso para la producción de una estructura portante de carga de titanio
SMT201500264B (it) Mutanti della frataxina
ZA201404499B (en) Trpm8 antagonists
PL2760629T3 (pl) Budowa struktury stożkowej
IL230217B (en) New mutations ecd–r17–il
GB201218275D0 (en) Scalloped landing ring
EP2786150A4 (en) DETECTION OF MULTIPLE ANALYTES
GB2510524B (en) Pulmonary hypertension
ITTO20110857A1 (it) Procedimento per la produzione di cicloesanonossina.
GB201103569D0 (en) Mutants
GB201118359D0 (en) Pulmonary hypertension
IT1403442B1 (it) Pneumatico e metodo per la costruzione di un pneumatico
ITMI20131683A1 (it) Componente strutturale microelettromeccanico e procedimento per la produzione di un componente strutturale microelettromeccanico
IL216586A0 (en) 3d-layout of the two tablets of testimony
PL395032A1 (pl) Brama rolowana segmentowa
BR112014012434A2 (pt) método de produção de cinacalcet, e, uso cinacalcet